| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2012-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a594885ca43d867724fab4f66033f77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afef0756b5808b39e1a93db6b0a0e363
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8eb79e764b192051775d6edc95ce08db |
| publicationDate |
2015-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9045540-B2 |
| titleOfInvention |
Anti-glycoprotein VI scFv fragment for treatment of thrombosis |
| abstract |
The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly 4 Ser) 3 peptide and followed by a “c-myc” flag, represented by SEQ ID NO:1. The invention also concerns functional variants of said scFv 9O12.2 fragment with identical heavy and light chains complementary determining regions 1, 2 and 3, and preferably humanized functional variants such as the humanized scFv fragments represented by SEQ ID NO:28 or SEQ ID NO:47. The invention also relates to nucleic acids encoding such a scFv fragment, expression vectors and host cells to produce such a scFv fragment, as well as therapeutic uses of such a scFv fragment. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10842870-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11692033-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018236071-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019367608-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015098939-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9441040-B2 |
| priorityDate |
2006-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |